I am Hirai from the IR and Corporate Communications. I will be serving as a Moderator today. I will now explain how to participate in this meeting. Simultaneous interpretation between Japanese and English will be provided for this briefing. You can select the language of the presentation materials displayed as well. Instructions on how to set this up are provided in the Zoom chat box, so please use them as needed. Please note that due to the setting of the audio equipment, our presenters' individual microphones are set to mute.
We ask for your understanding that the audio will be delivered from an account different from those of the presenters. Let me introduce today's presenters: Kyoko Deguchi, Representative Director, President, and CEO; Kaiju Yamaguchi, Director, Senior Managing Executive Officer, CFO. After both of them have given their presentations, there will be time for questions and answers. Now, Deguchi-san, please go ahead.
Good afternoon, everyone. I am Deguchi, the President and CEO. Today, I will present an overview of our financial results for the second quarter of the fiscal year ending in March 2027, as well as our full-year earnings forecast. This time, we have revised upward our full-year forecasts. I will present the executive summary, and our CFO, Yamaguchi, will explain the second-quarter financial results and the full-year earnings forecast. Here are the financial highlights for the first half of the fiscal year. Continuing from the first quarter, we significantly exceeded both our internal targets and last year's figures. Revenue was JPY 180 billion, representing a year-on-year increase of 3.8% or JPY 6.6 billion. In diabetes management, BGM maintained a strong performance from the previous year despite market contraction in developed countries. This offset the revenue decline resulting from the CGM divestiture, achieving a 12.3% increase in revenue.
In the healthcare IT solutions, revenue declined due to server supply shortages coming from the recent surge in demand for AI-related semiconductors. The life sciences segment saw revenue growth, primarily in U.S. and Asia, returning to year-on-year growth, even excluding the impact of foreign exchange rates. Operating income was JPY 19.4 billion, an increase of 87.3% or JPY 9.1 billion year-on-year. This increase was driven by higher revenue from BGM, particularly in the highly profitable European market. The impact of U.S. tariff refunds and improvements resulting from the CGM divestiture offset the decline in profit from healthcare solutions. This led to a significant improvement in profit margins. The company-wide operating profit margin was 10.8%, an improvement of 4.8 percentage points compared to the previous year. Both revenue and operating income reached record highs for the first half of the fiscal year.
Net income attributable to owners of parent increased by JPY 13.9 billion. In addition to positive impact of higher operating income, this increase was driven by foreign exchange gains in the current period. The previous year's period was significantly impacted by foreign exchange losses. The interim dividend was set at JPY 21 per share, as previously forecasted. Next is a full-year earnings forecast. Based on the results through the second quarter and current exchange rates, we are increasing our full-year earnings forecast by JPY 6.3 billion for revenue and JPY 6.0 billion for operating income. We have updated the exchange rates to JPY 182 per euro and JPY 159 per US dollar. Revenue reflects strong first-half performance in diabetes management, including the positive impact of exchange rate revisions. We are revising the forecast upward to JPY 11.4 billion.
This will offset the revenue decline resulting from the CGM divestiture, and we expect revenue to increase year-on-year. In healthcare solutions, we expect a decline in revenue due to server supply shortages. However, in diagnostics and life sciences, we have revised our forecast upward, reflecting the strong first-half performance of the life sciences business and the positive impact of exchange rate changes. We need to continue to monitor the persistently soft demand for equipment in the pathology business during the second half. However, we expect the life sciences business, where recovery in the U.S. is becoming apparent, to exceed expectations. Regarding operating profit, healthcare solutions has revised its forecast downward to account for the impact of lower revenue. However, diabetes management has revised its forecast upward by JPY 8.1 billion, with a full-year operating profit margin of 31%.
This is based on positive revenue growth from blood glucose monitoring, or BGM, in highly profitable markets such as Europe and the U.S. in the first half. We also anticipate a JPY 1.4 billion increase in profit for diagnostic life sciences due to improved profitability driven by the impact of tariff refunds and price revisions in the first half. As a result, we project a company-wide operating profit of JPY 33.0 billion, with an operating profit margin of 9%. Regarding financial income and expenses, we have reflected foreign exchange gains recorded in the first half and increase in interest expenses resulting from recent interest rate hikes. Consequently, profit attributable to owners of parent is projected at JPY 18.0 billion, an upward revision of JPY 2.6 billion. Regarding dividend, we will maintain the year-end dividend at JPY 21. The annual dividend per share remains unchanged at JPY 42.
Next, the progress of our businesses. Ascensia, which operates the diabetes management business, has entered into a business alliance with Sava Technologies. The purpose is to re-enter the growing CGM market by supporting the launch and sale of a CGM that adopts the microsensor technology developed by Sava. The microsensor developed by Sava is expected to enable continuous glucose monitoring that is less invasive and lower in price compared with existing CGMs. Furthermore, it is designed to continuously monitor biomarkers and molecules other than glucose as well, and it is a product that is expected to be utilized in the future as a new method for monitoring health conditions and diseases more broadly. Under this agreement, Ascensia, which boasts a high recognition in the diabetes care field and has a strong business base in Europe, will become the exclusive distribution partner first in Europe.
We assume that we will be able to develop the business by utilizing the channels of BGM, our current core business, and existing insurance reimbursement systems. This is a strategy aimed at the CGM rollout that makes better use of our strengths. The product is scheduled to be launched in Europe after Sava obtains CE marking, and we expect sales to begin as early as the fourth quarter of FY 2027. In the diagnostics and life sciences field, Epredia, which operates the pathology business, has formed a business alliance with Leeds NHS, a large hospital group in the U.K. that is also one of Europe's leading digital pathology research centers. Epredia will utilize Leeds' technology to develop new pathology glass slides and promote the global rollout of Leeds' advanced technology.
In addition, in terms of IR activities, we were featured in The Securities Analysts Association of Japan's Good Disclosure Practices. We received recognition for the initiatives we have continued to date, such as enhancing information disclosure and holding briefings to promote understanding of our businesses. We will continue to strive to enhance our communication of information going forward. We published this fiscal year's edition of our integrated report last month. With the theme "Visualizing Our Story," the report visualizes and explains in depth our strengths of precision technology through a systematic overview by our CTO, Chief Technology Officer, a feature on manufacturing at the Matsuyama plant, and introductions to the technologies of each businesses. We would be grateful if you would take the time to read it. This concludes my explanation. I will now hand over to Yamaguchi, our CFO.
First, I will explain the results for the second quarter. Then I will explain the full-year earnings forecast, which we have revised this time. First, here is an overview of our second quarter results. Cumulative revenue increased 3.8% year-on-year to JPY 180 billion, while operating income rose 87.3% to JPY 19.4 billion. This marks a significant increase in profit for the second consecutive quarter. Revenue increased by JPY 6.6 billion, and operating income rose by JPY 9.1 billion. The impact of the CGM divestiture carried out in the previous fiscal year resulted in JPY 1.9 billion decrease in revenue, but JPY 4.2 billion increase in operating profit. Additionally, the effect of U.S. tariff refunds improved operating profit margins across all business segments, except healthcare IT solutions. Pre-tax profit also increased significantly by JPY 16.1 billion to reach JPY 17.0 billion.
In addition to the increase in operating profit, the main factor was JPY 6.8 billion exchange loss in the previous year turned into JPY 1.0 billion exchange gain in the current year. Profit attributable to owners of parent increased by JPY 13.9 billion to reach JPY 13.3 billion. EBITDA increased by JPY 8.9 billion year-on-year. Adjusted EBITDA, which excludes one-time gains and expenses, increased by JPY 9.2 billion to reach JPY 33.5 billion. Favorable exchange rates played a role, but as in the first quarter, all metrics exceeded both previous year figures and internal targets. The exchange rates applied for the second quarter were JPY 184 to EUR and JPY 159 to USD, both of which represent significant yen depreciation from the previous year. This page shows quarterly trends in revenue and operating profit.
Revenue declined slightly compared to last year and last quarter, primarily due to a decrease in healthcare IT solutions revenue. Although BGM revenue decreased compared to first quarter, which benefited from time difference, demand remained strong, particularly in Europe. Additionally, the life sciences segment, which is recovering in the U.S., experienced revenue growth compared to the previous year and previous quarter. Operating income increased significantly year-on-year due to strong performance in BGM and life sciences, as well as the impact of CGM divestiture and U.S. tariff refunds. However, compared to first quarter, operating income decreased. I will explain the situation regarding healthcare IT solutions in more detail later. This shows revenue by segment and business. in this quarter, we have been implementing reorganization within diagnostics and life sciences, and previous fiscal year's figures have been restated. Please refer to page 31 of the appendix for details.
Despite the revenue decline resulting from the divestiture of the CGM business, diabetes management revenue increased by 12.3% year-on-year and by 2.3%. Even excluding the impact of exchange rates, revenue in blood glucose monitoring increased due to continuous strong performance in Europe and emerging markets. Despite the ongoing market contraction in developed markets, the segment continued to perform well by gaining shares, including impact of timing difference in the first quarter. BGM revenue alone increased by 6.4% year-on-year, excluding foreign exchange effects. In healthcare solutions, clinical testing and CRO performed well, but were not able to offset the decline in healthcare IT solutions revenue, resulting in 5% overall decrease. The diagnostics and life sciences saw 6% increase in revenue. Demand for equipment remained stagnant, but sales of consumables were strong, and there was positive impact of currency.
The life sciences segment performed particularly well in the U.S. and Asia, resulting in 2.3% growth even after excluding foreign exchange effects. Although the life sciences equipment segment has been affected by market stagnation in the U.S. since FY 2023, we believe signs of recovery are finally emerging. I will now explain the breakdown of year-on-year changes. The graph above shows revenue. In this period, the yen weakened against both the euro and the dollar, resulting in a positive exchange impact of JPY 9.3 billion. While diabetes management, clinical testing, CRO, life sciences saw revenue growth, significant revenue decline in pathology and healthcare IT solutions led to 1.5% decrease on an exchange-adjusted basis. The graph below shows operating income. Although healthcare solutions experienced a decline in operating income, diabetes management posted a substantial increase. Additionally, diagnostics and life sciences profits increased.
This resulted in an 76.2% increase in operating income, even without the effects of foreign exchange. Now, I will explain the results by segment. First is diabetes management. Revenue increased by 12.3% year-on-year, and operating profit rose by significant 99%. The operating profit margin remained high at 34%. While market contraction in developed countries and the shift toward low-price channels continue, and CGM divestiture impacted revenue, sales in Europe remained strong, particularly in Germany, Italy, and Greece. Additionally, growth in emerging markets was driven by recovery in the Middle East and contributions from Algeria, where local production began last year. Combined with favorable foreign exchange effects, this resulted in double-digit revenue growth.
Operating income increased significantly due to higher revenue, improved sales mix driven by revenue growth in developed countries, primarily in Europe, cost reductions resulting from structural reforms, reduced losses from the CGM divestiture, and favorable foreign exchange rates. Even excluding the impact of the CGM divestiture and foreign exchange effects, operating income increased by JPY 4.1 billion. Next is healthcare solutions. Revenue decreased by 5% year-on-year. Operating income fell by 84.5%, and operating margin deteriorated from 4.7% to 0.8% from the previous year. In clinical testing, revenue increased due to rise in general testing and higher sales in genetics field, which is the company focus area, as well as the progress in optimizing sales prices. CRO revenue increased due to rise in the order backlog and the completion of a large-scale safety trial. On the other hand, the healthcare IT solution saw a 19% decline in revenue.
Although sales of electronic prescriptions increased, sales of electronic medical records decreased. In selling on-premise electronic medical records, we deliver a package consisting of software and service for data storage and processing. A surge in demand for AI-related semiconductors has caused a server supply shortage, resulting in delays in selling electronic medical records to customers. Despite increase in electronic prescription sales, progress in optimizing clinical testing prices, and improvements in the CRO segment, operating income declined significantly. This was largely due to the revenue decline in the healthcare IT solutions and one-time expenses related to retirement benefits resulting from last year's merger with Wemex and its subsidiaries. Finally, diagnostics and life sciences. Revenue increased by 6%, while operating profit rose significantly by 153.5%. The operating profit margin was 6.5%. In pathology business, sales of consumables remained steady across all regions, and price revisions had a positive effect.
However, revenue declined without favorable impact of exchange rates due to stagnant demand for equipment and absence of a major digital pathology contract this year. Life science business experienced revenue growth driven by robust life science equipment sales and favorable foreign exchange rates. Sales of life science equipment were strong in the Americas, Asia, and Japan. Despite continued government budget constraints, sales to pharmaceutical, biotech, and hospital sectors were strong in the U.S. IVD revenue declined due to lower sales in the Americas, despite strong performance in Europe and Asia. Please refer to page 27 for breakdown of life sciences revenue according to the previous classification. Operating income increased due to improved profitability driven by higher life sciences revenue, price revisions, cost-cutting measures, and the impact of U.S. tariff refunds, the favorable exchange rates. This is revenue by region. Including FX impact, revenue increased in all regions except Japan.
Japan saw a decrease in revenue due to the impact of healthcare IT solutions. Europe saw an increase in revenue due to the strong performance of diabetes management. North America saw an increase in revenue due to solid sales of life science instruments and positive FX effects, and other regions saw an increase in revenue owing to the growth of diabetes management in emerging countries and the expansion of solid sales of diagnostics and life sciences in Asia. This page shows the adjustments from operating profit to adjusted EBITDA. Depreciation and amortization was JPY 13.3 billion, the same level as in the previous year. As for the adjustments from EBITDA to adjusted EBITDA, M&A-related expenses of JPY 690 million were recorded in the current period, compared with JPY 80 million in the previous year. The current period includes retirement benefit-related expenses arising from the merger.
Structure reform-related expenses were JPY 450 million in the same period last year and JPY 110 million in the current period. Next, I will explain the main assets and liabilities on the consolidated BS. Interest-bearing debts was repaid by a net of JPY 11 billion, and including FX impact, the balance decreased by JPY 12.3 billion. The net leverage ratio declined from 3.7 x to 3x due to the decrease in net interest-bearing debt and the increase in adjusted EBITDA. ROE also improved significantly to 9.1% due to the increase in profit attributable to owners of the parent. The goodwill balance was JPY 217.7 billion. There was no change on a local currency basis, but it decreased by JPY 3.8 billion because the yen was stronger at the end of the second quarter than at the end of the previous fiscal year.
Operating cash flow was JPY 21.2 billion, reflecting strong business performance. Investing cash flow was an outflow of JPY 5 billion, including capital expenditure of JPY 4.6 billion. Financing cash flow was an outflow of JPY 16.7 billion due to the repayment of lease liabilities and the payment of dividends, in addition to the repayment of the borrowings of JPY 11 billion. Total cash flow was JPY -600 million, and together with a decrease of JPY 1.5 billion due to forex impact, cash and deposit decreased by JPY 2 billion. Working capital increased somewhat in the first half, so we intend to keep this firmly under control in the second half. Next, I will explain the full-year earnings forecast, which we have revised this time. We have revised revenue upward by JPY 6.3 billion and operating profit upward by JPY 6 billion.
The changes in each segment will be explained on the next page. Taking actual rates into account, we have changed the assumed exchange rate to JPY 182 to the euro and JPY 159 to the US dollar. We forecast a profit before tax of JPY 26.7 billion, an increase of JPY 4.7 billion. We have factored the FX gain recorded in the second quarter results and increase in the interest expenses due to the rising interest rates into financial income and financial costs, respectively. Factoring in the increase in tax expenses associated with increase in profit before tax, we are revising profit attributable to owners of the parent upward by JPY 2.6 billion-JPY 18 billion. This page shows the comparison with the previous forecast by segment. As for revenue, diabetes management reflects the strong performance in Europe, the U.S., and the Middle East in the first half.
For diagnostics and life sciences, we expect the impact of stagnant instrument demand in the pathology business, but have factored in the strong first-half performance of life sciences. We have revised both segments upward, also adding the FX positive impact. On the other hand, for healthcare solutions, although the effect of increased testing-related sales, such as genetic testing and of sales price optimization in the clinical testing, are expected to continue, we are revising the forecast downward to factor in the decrease in electronic medical record sales due to the server supply shortage in healthcare IT solutions. As for operating profit, diabetes management has been revised significantly upward by JPY 8.1 billion, factoring in the strong first-half results and the positive FX impact. For diagnostics and life sciences, we also expect an increase of JPY 1.4 billion, reflecting first-half results, including the tariff refunds and FX.
Healthcare solutions has been revised downward by JPY 3.5 billion, factoring in the impact of the decrease in revenue. Now, I will explain the upside and downside for the second-half outlook. Diabetes management continues to perform well at present, and we believe there is upside if a strong performance in Europe and the U.S. continues into the second half. On the other hand, although the expansion of the insurance reimbursement for CGM is currently behind what was assumed, there is a possibility of reimbursement expansion in several European countries, among other factors.
Downside risk has begun to emerge. For this fiscal year, we have built our outlook on the assumption that the risk is not that large at this point. As for the life sciences businesses in the U.S., where market conditions had remained stagnant, sales of life science instruments such as ultra-low temperature freezers have been increasing, and a market recovery is coming into view. We believe there is upside if this trend continues into the second half. On the other hand, in the pathology business, although sales of consumables remain solid, stagnant demand for instruments continue, and the business is still on a weak note, excluding forex. We believe there is downside risk. In addition, base interest rates in the U.S. are rising, and we believe we need to carefully examine the risk of impairment as well, together with business performance.
Both diabetes management and diagnostics and life sciences are affected by FX. If rates fluctuate from the current assumed rates, based on actual rates, yen appreciation will be a negative factor, and yen depreciation a positive factor for revenue and operating profit. As for healthcare solutions, the forecast for clinical testing and CRO basically reflect the strong first half. As in previous years, CRO expects a large amount of revenue to be recorded in March, and we believe there is a certain degree of risk. Healthcare IT solutions, which is affected by the server supply shortage, will be explained on the next page. Healthcare IT solutions saw a decrease in revenue in the first half due to the impact of server supply shortage caused by increased AI-related semiconductor demand.
First, regarding the current status of server procurement, delivery delays and price negotiations have arisen even for servers already ordered, and the negotiations are still ongoing. However, at this point, we have a rough view of securing the necessary quantities, and we believe the risk is decreasing as we work to mitigate the impact in the second half. The impact of this matter on first-half results was approximately JPY 4 billion in revenue. For the second half, we believe we can contain the impact by securing a certain number of servers while negotiating prices in the third quarter and by implementing further countermeasures, such as securing alternative suppliers in Q4.
In addition, we aim to restore business performance by accelerating sales of the cloud-based electronic medical record system launched last year, while reliably capturing special demand related to healthcare DX, such as electronic medical record, information sharing service, and electronic prescriptions. In connection with our initiatives to improve performance in the second half, I will explain healthcare DX and the recently announced certification system for standard specifications of electronic medical records. Demand related to healthcare DX is expected to continue. The electronic medical record information sharing service is scheduled to start in January 2027. Subsidies for electronic prescriptions have been partially extended, and demand related to online eligibility verification also continues. We participate in product working group for the standard electronic medical record, where we respond swiftly to policy and make recommendations from a frontline perspective, among other activities.
Regarding the certification system for standard specifications of electronic medical records and its requirements announced in October, our products already meet the main requirements, and we expect to meet the requirements of operation at 200 or more facilities within this fiscal year. As has already been announced, toward a 100% electronic medical record adoption rate in 2030, not only the spread of cloud-based systems, but also the use of on-premise systems, which are currently mainstream, has been factored in. Although on-premises systems are not covered by the certification system, most of our electronic medical record systems have specifications that can support healthcare DX.
For our part, while firmly capturing healthcare DX-related demand, we will expand sales of cloud-based electronic medical record and strengthen our cloud capabilities. In addition, we will continue to offer a full lineup of products, including on-premises and hybrid types, and maintain a structure that meets customer needs. Comparisons of the revised full-year forecast with the previous year and the previous forecast are shown, but I will omit a further explanation. That concludes my presentation. Thank you.
We will now move on to Q&A session. Koichiro Sato, the Representative Director, Executive Vice President, Chief Operating Officer, and Chief Strategy Officer, will join us as a respondent. If you have a question, please click the raise hand button at the bottom of the screen. When your name is called, your microphone setting will be adjusted. Unmute yourself, state your name and organization, and ask your question. If you have a question, please raise your hand. I will call on participants in the order in which they raised their hands. Hidemaru Yamaguchi-sama, the floor is yours.
This is Citigroup Yamaguchi. Do you hear me? Yes. Thank you. I have several questions. The first is about the server. This is including basic things. With the situation, your sales are down. For customers, also, are they in trouble? What about the opportunity loss? As long as you can ensure the service, you will be able to sell to customers from next quarter on, or the situation may allow your competitors to snatch your customers. You also said that you are trying to improve the supply chains to ensure the service, but to be specific, what are you doing?
Thank you for the question. This is Sato to answer your question. First, the server shortage response. We are currently receiving supply of servers to suppliers, and we are ensuring a certain number of servers that we have ensured, and I believe that we have enough supplies for the third quarter and beyond. With regard to the server prices, we believe that the prices will have to be higher. So, to a certain extent, we are passing on the increase to customers. The other thing is PC servers can be utilized so that we can absorb the rise in the prices. That's what we are thinking. These are some of the specific measures that we are taking. With regard to your first question, it depends on the switching timing of our customers. We want to make sure that we can offer them servers to existing customers.
We have clinic customers, and we have cloud systems which can be offered to them. However, with regard to dispensing pharmacies, there ought to be hardware to be there to offer the systems solutions to them. So, with regard to dispensing pharmacies, we would like to make sure that the new servers we captured will go there. From the third quarter on, we would like to make sure that we can absorb the higher prices. We may pass on some of the prices, or we may utilize PC systems to alleviate the increase in the price.
I do not think you directly answered my question. You are not losing your customers.
Yes, that's exactly right. We are late in delivering systems to them. We are not losing customers.
The next question is about CGM. You have Sava Technologies that you mentioned. You have previous experience, and I do not know what exactly new about that. But compared to the existing systems, you said that Sava systems are very much differentiating, and it ought to be commercially successful. However, in the previous case, that was an implanted system, and you terminated the relations. But what about this time? Is it going to be a success, including the competitiveness and the difference with the existing system? Could you please elaborate?
I believe that the previous case was Senseonics. This time, it is Sava Technologies, and this technology does not require implantation. Compared to the existing CGM, it is very much less invasive, and also, it has a cost advantage overall. Furthermore, with this unique structure, the system can measure multiple biomarkers. That's another advantage. That is a difference with existing Eversense and existing CGM system. That's where the competitive advantage comes from.
So, you said that in Europe, you obtain CE mark, and eventually you will go into U.S. market?
Yes, we will obtain CE mark to go to European market first. This is reflecting on our things with Eversense, because there is a higher presence, and we believe that we can utilize the same channels to offer the solutions. That is why the marketing and sales costs can be limited. We want to make sure that there is synergy. That is why we want to start with the European market. We want to make sure that we will be a success there, and then we will go into the U.S. market.
Thank you.
Thank you very much. Next is Mr. Masao Yoshida, please.
Thank you. I am Yoshida from Tokai Tokyo. Thank you for your presentations. I also want to ask a question about server that Mr. Yamaguchi asked the question. As a differentiator, you explained, and it is expected to be competitive. But when it comes to the precision, compared to existing CGM, even for the existing CGMs, some users, I hear, saying that they doubt whether or not always accurate figures could be actually shown. What about the blood glucose measurement, this numeric precision or accuracy? What about the speed of measurement or invasiveness? I think my understanding is that the needle, in this case, your new product, wouldn't go deeper inside of the skin. Could you describe a little more about less invasiveness of this and also overall the competitive advantages?
R egarding the accuracy. Accuracy is almost equivalent to that of existing CGM, and we have confirmed on that point. As for the speed, it is also the case with the current CGM. Our product uses the same adoption criteria when it comes to looking at the interstitial formation, rather than measuring it in blood. There is a bit measurement speed lag, and that's not much different from existing CGM. Current existing products, no difference in terms of speed. But the companies are emphasizing that improving the user experience in the app, in the AI area, and they are aiming to do with it more advantageous provisions of data to the users. More intuitively, the design is made for easier use by the customers. That's the difference.
I see. Thank you. You used to have Senseonics, and you spent substantial SG& A expenses, but currently, you are starting first limited in Europe. Therefore, can I consider that you won't spend too much marketing expenses and so on to start up? Do we need to consider a certain amount of expenses will be needed to be spent in advance?
Well, I think that we need to strengthen some sort of functions of the company, but it's not like the case of Eversense that will be having independent organization in that case. Marketing cost, selling cost, those could be controlled low, and that's what we have been leveraging the learnings from the experiences with Eversense. If I make a supplement about the necessary investment, Sava doesn't have any approved products, so they are conducting testings and try to get a CE mark. As Sato mentioned, regarding accuracy, it is comparable to existing CGM. Adjunctively, the insulin injectable accuracy could be actually produced. With that accuracy, we will be going into the market. For us, we believe that we will be able to make use of BGM existing channels.
Therefore, different from the cases of Senseonics, which needed the implanting infrastructure, we do not think that any major investment will be necessary in this case. Of course, it is a new product launch and marketing, therefore, to a certain degree, we will spend the cost. Compared to Senseonics cases, we believe that we will be able to leverage existing capabilities much better. Also, starting from Europe, where we have a good established base, we will be able to quickly start up and ramp up our businesses there. That is what we are considering about the investment. Thank you.
My second question is about the server. Same question as before. On-premise type clinic, electronic medical records. There are some companies handling those. I just attended their briefings, and they did not talk about any server supply shortage. What is the overall situation here? Are there any specific problematic situation in your company, or you have a high market share as a result, you are handling a big amount of servers, therefore you had a shortage of necessary amount of server supply?
Overall, globally, because of AI demand increase, overall, the supply is in shortage. That is the overall situation. Because our market share is so high, regarding the on-premise leverage and try to provide our specific servers, that is also impacted because of overall server supply shortage.
Now you had the downward impact incurred in the first half, and also for the full year. If delivery is going to delay, then I think that share would be also taken by some other players. Could you elaborate on that once again, although this question might be overlapping with the previous ones?
In the second quarter, hardware supply couldn't be actually provided. Therefore, we lost almost three months' equivalent quantities. Starting from the third quarter to the fourth quarters, we will be recovering the supply to the customers. Therefore, we already had received demand or orders. Then with the priority, we have been supplying to all the orders already placed. Therefore, we are not losing anything in that sense, but already orders are received, and we are currently providing to those orders.
Currently, do you have to ask the customers to wait for another moment in the second half?
No, no. The supply has already started, and we secured the supply. Therefore, although it is somewhat delayed, we are continuously supplying. For the server introduction itself, of course, it takes processes or steps. For the second quarter's impact, then switching to cloud, and also as a back order, we do have some customers waiting for our provision. Starting from the third quarter, we will get the supply of servers. Therefore, we start supplying our servers to the customers waiting, being on a waiting list. However, of course, it takes certain efforts or processes. Therefore, in that sense, depending upon the supply, we would like to actually solve all those backlog of orders. That is a process that we expect to take place.
Thank you very much. Just last point regarding life science. Due to Trump initiatives, you had various turmoils. However, Republicans lost, Democrats won. Then what would be a potential impact? Could you give us updates? Any stories you are hearing from the customers or any investment directions in the U.S.? Are there any changes?
Well, at the moment, we do not see any major developments. But so far, government-related sectors or pharmaceuticals, biotechs, those have been particularly contained due to the administration's initiatives. Now, I believe that they are retracting, and the recovery will be gradually seen.
Next, Tokumoto Shinnosuke-sama, the floor is yours.
This is Nikko Shoken Tokumoto. Do you hear me?
Yes.
Thank you. About BGM sales, you said that sales are brisk, and you said that you revised upward, but still there is an upside opportunity. So what about the BGM, the continuation into the second half, and the CGM will be subjected to insurance coverage and impacting BGM? So at this point in time, to what extent you revised the upward for BGM sales in the second half, and what about the size of the further upside on BGM sales in the second half?
Thank you for the question. That was a question regarding BGM. As I have explained, currently, the BGM sales are brisk. If this trend continues, then there will be a certain level upside. Having said that, just as I have mentioned in Q1, the market itself is declining. That is why in Q2, we will be able to ensure the share, and compared to the previous year, we were able to have better sales. But Q2, the trend is a little bit weaker than Q1. That is why in the second half, we are seeing a certain level of risk regarding BGM. About CGM expansion of insurance coverage, in some countries, from January 1st, insurance coverage will be given to CGM. So that is also impacting BGM. That is why we made this forecast. If the impact is smaller, then there is still a possibility of further upside.
Understood. Thank you. The second question, that is about CGM Alliance. The previous questioner asked a question, that is about Sava. So this is 1 mm or less needle. This is very less invasive system, that is Sava. But you have Libre and Dexcom G7. For these systems, invasiveness is no longer an issue. So to what extent this less invasive nature has a competitive advantage? The other thing is that this is 15-day use. 15-day use, and what about the results of the clinical studies, and what about the time span? Libre and Dexcom, we believe that that is 10-day system that was proven. So unless you can prove with 15 days, it will be difficult for you to gain the market.
Thank you for the question. With regard to invasiveness, this is micro needle, and we do not have the exact product yet. That is why the invasiveness is not an issue. But if we actually apply the two sides simultaneously, one can feel the difference. So if we go into the market, then we will be able to appeal to the patients better QOL with Sava systems. With regard to clinical studies, currently, the studies are underway, and that is why we are not allowed to mention anything about the clinical studies. Sorry about that.
Understood. Thank you.
Thank you. Next is Mr. Seiji Wakao, please.
Thank you. I am Wakao, JPMorgan. Thank you. I would also like to ask a question about Sava. You are starting your business in Europe, and what is your expectation? The positioning is the same as Senseonics that you did in the past. Currently, the forecast is a bit uncertain. Therefore, you would like to grow with CGM. That story you believe that you will be able to construct with this product, and for that, not just in E.U. but also in U.S., you need to roll out the business, although it may take time. Is there any potential or possibility to operate this business in the U.S.?
Sava, just regarding how to pronounce the naming, it is from French, [Non-English content] . Please note, that is how the name should be pronounced. As Wakao mentioned, we will be starting from Europe. BGM overall trend is to shrink. Therefore, from our side, we would like to protect this as much as possible. On top of that, we would like to see a new growth with CGM. That is the story we are thinking about. As you said, the U.S. is the largest market. Therefore, we would like to consider the U.S. market. Having learned from our previous experience, if we go for U.S. alone, we need large-scale investment and so on and so forth. Therefore, first, we would like to get the CE mark, and we would like to secure the good achievements where we are strong, and then we would like to consider the U.S. entry.
What would be the timing for you to consider U.S. entry?
It depends on the FDA's approval, but FY 2029 is what we are considering.
Thank you. I understood. Second question is about diabetes management, second half forecast. Yamaguchi-san explained in the second half, the risks may be too large, and that's the impression I had from his presentations. Looking at the second half plan, amongst the three segments, I believe that compared to the first half, the healthcare solutions, I thought that it's quite uncertain. Therefore, this conservative-looking forecast, does it include the buffer for such uncertain business forecast? Or what is the appropriate scenario for us to consider about this forecast and your plan for the second half?
In the first half, thank you very much for your question, we had some effect from last year, phase shift. Even if excluding that impact, I think that the second half may look a bit weaker as a matter of fact. In the first half, the market situation was favorable for us. In Europe, the bidding timings delayed or a certain high pricing items sold well. We could get market share, so on and so forth. Therefore, very positive achievement we could attain in the first half.
I am repeating, for the second half, there is a certain downside risk, although we don't think that there are any big risks considered at this point in time. But we factor in a certain degree of risks. Therefore, for the upward revision of the first half, that's actually reflected in the forecast. If favorable market situation continues, then I think this upside, at least for BGM, I think we will be able to generate. It is not necessarily the buffer, but for overall group, upside, downside, there could be both. From my position, including them all, we would like to achieve what we plan.
Thank you.
Thank you. Next is Hayashi Ryotaro-sama.
Thank you for the opportunity. Morgan Stanley Securities. My name is Hayashi. Do you hear me?
Yes.
I have two questions. The first question, this is overlapping the previous questions, but Diagnostics & Life Sciences, the demand situation in the U.S. in the second quarter, the sales seem to be recovering to a certain extent, but is that true? What about the orders? Are orders recovering more than sales? Your market is the U.S. What about the reasons for the U.S. market that is recovering? That trend is already occurring before the midterm elections. Now we have the results in the elections. Will this further push up the demand for life science and diagnostic products? That is my first question.
Thank you for the question. First, the U.S. from the second quarter on, we are seeing the signs of recovery. That was a question, and the answer is yes. We had Trump tariff impact, and that was holding down the investment. From the second quarter on, the orders are coming back. This is true not only with us, but with the industry as a whole.
What is the driving force? That was the second question.
Biotech and pharmaceutical companies, these are impacted by Trump administration's policies. They are subjected to high level of tariffs unless they have production base in the U.S. That is why some biotech companies and large pharmaceutical companies are beginning to shift their production sites in the U.S. Of course, these are the big facilities, so it is not overnight issue, but they are gradually shifting the production bases into the U.S. That is one driver for us and for the industry. Now the midterm elections are over, and this is immediately after the election results are available.
We will continue to monitor the impact, but probably it is possible that it has a favorable impact because there are lots of things that have been stopped, including the FDA giving the approval, the staff shortage, and according to the market, there could be a favorable situation. The Democratic Party won both the upper and lower houses, and we believe that this is going to a positive move. That is why in the second half, particularly in the biomedical, there could be an upside potential. I think I answered your three questions.
Thank you. The second big question is as follows. The Trump administration's impact. What about the impact on the figures in the second quarter or in the first half? What about the impact of tariff refunds? You have the full- year forecast. In the second half, the tariff refund impact will be zero. What about your assumption?
Thank you. I was going to augment. In Q1, I believe that was also a question asked and answered. In the second quarter, $10 million tariff refund was realized with Diagnostics & Life Sciences. From the second half on, we do not include any tariff refunds.
This second quarter figure is exactly as you anticipated?
Yes. That tariff refund was realized in Diagnostics & Life Sciences segment. That is correct.
Thank you.
Next is Kei Takeuchi, please.
Thank you very much. I am Takeuchi, BofA Securities. Just one question quickly. I might miss something. If so, I am sorry. Regarding the healthcare solutions segment, expenses record, the retirement benefits and the structural reform. Could you tell me roughly how much that is for structural reform as well?
Adjustment amount is around JPY 100 million or so. That is page 18 of the slide deck. Showing the healthcare solutions temporary M&A-related gains and expenses, there are 786. Those are the parts. It is non-cash expenditures and retirement benefits and the pensions of a confirmed benefit pension, and the restructuring budget temporarily, that is also shown below.
Thank you.
Thank you very much for all the questions asked. With this, we would like to conclude this briefing.
Thank you very much for your participation.